Name: Telix Pharmaceuticals (TLX) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

TLX

Telix Pharmaceuticals

Pharmaceuticals, Biotechnology & Life Sciences

Telix Pharmaceuticals is a global biopharmaceutical company specializing in the development and commercialization of radiopharmaceuticals for cancer treatment. The company focuses on precision oncology, utilizing targeted radiation to treat urologic, neurologic, and musculoskeletal cancers. Telix's unique value lies in its ability to deliver focused radiation doses with precision targeting, minimizing damage to healthy tissues.

Short position

short percentage10.51%

reported shorts35.7M

shares on issue339.892M

Telix Pharmaceuticals (ASX:TLX) has 10.51% of its shares on issue reported as short positions as of 22 Sept 2026, or about 35,710,036 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has fallen 2.07 percentage points. Its highest recorded short interest was 16.51% in April 2026. TLX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Weekly context: The 10 most shorted ASX stocks — Week 39, 2026.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

TLX intelligence dossier

Public-source evidence for this company, with industry drill-up links.

Tax paid and taxable income records
Government contracts and public money
Emissions and trade exposure
Political donations and lobbying links

Short interest history & FAQ

TLX Short Interest History

30-day change: -0.04pp
90-day change: -2.07pp
1-year change: +3.54pp
All-time high: 16.51% (April 2026)
All-time low: 0.00% (February 2021)

Is TLX heavily shorted?

Yes. At 10.51%, TLX is one of the most heavily shorted stocks on the ASX, ranking #10 of 809 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.

How has TLX's short interest changed recently?

Over the past 30 days Telix Pharmaceuticals's short interest has been broadly stable, and over 90 days it has fallen 2.07 percentage points. The current level is 10.51% of shares on issue.

What is the highest TLX's short interest has been?

Since 2017, Telix Pharmaceuticals's short interest peaked at 16.51% in April 2026 and bottomed at 0.00% in February 2021.

Where does this data come from?

All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2017. See our methodology.

TLX fundamentals

In the year to 30 Jun 2025, Telix Pharmaceuticals (ASX:TLX) recorded revenue of A$803.8M. A year earlier it recorded revenue of A$783.2M. Year-on-year growth: revenue +2.6% (FY). Net margin 40.9% (FY). Figures are in AUD, the company's reporting currency; source: Company filing (extracted), as at 28 Sep 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Strategy fit

How each stock picker strategy reads TLX today

PassFailUnknown (data missing, or not meaningful for this company)

Zanger Breakout
WatchScore 29rank 314 of 1833
- 1. Explosive growth: fail. Revenue +2.6% YoY (FY ending 2025-06-30); below the +25% threshold
- 2. A recognisable base: pass. 27-session base, 23.4% deep; close A$16.09 holds above the base low A$13.95
- 3. Breakout on heavy volume: fail. No close above the A$18.22 pivot on 1.5x volume in the last 5 sessions; close is -11.7% from the pivot
- 4. Read the market first: fail. XJO in a downtrend: below its 200-day average
- 5. Relative strength: pass. Beat the S&P/ASX 200 by 5.9 points over 3 months
- 6. Liquid enough to trade: pass. A$41.8m average daily turnover over 20 sessions
CAN SLIM
WatchScore 25rank 196 of 1234
- 1. Earnings growth (C and A): unknown. No EPS growth figure yet
- 2. Sales growth: fail. Revenue +2.6% YoY (FY ending 2025-06-30); below the +20% threshold
- 3. New highs (N): fail. 11.7% below the 52-week high, more than 5% away
- 4. Leader, not laggard (L): pass. 6-month relative strength +16.0 points, in the top quartile (cut-off +7.8)
- 5. Market direction (M): fail. XJO in a downtrend: below its 200-day average
- 6. Supply and demand (S): pass. A$41.8m average daily turnover over 20 sessions
Minervini Trend Template
TriggeredScore 76rank 56 of 1768
- 1. Above rising averages: pass. Close A$16.09, 150-day A$14.62, 200-day A$13.56: stacked in order
- 2. 200-day trending up: pass. 200-day average A$13.56 vs A$13.14 a month ago (+3.3%)
- 3. Well off the low: pass. Close A$16.09 is 100.6% above the 52-week low of A$8.02
- 4. Near the high: pass. 11.7% below the 52-week high
- 5. Relative strength: pass. 6-month relative strength +16.0 points, in the top quartile (cut-off +7.8)
- 6. Above the 50-day: pass. Close A$16.09 vs 50-day average A$15.93 (+1.0%)
- 7. Liquid enough to trade: pass. A$41.8m average daily turnover over 20 sessions
Crowded-Short Breakout
SetupScore 56rank 7 of 1611
- 1. Crowded short: pass. 10.51% of shares on issue reported short
- 2. Days to cover: pass. 15.9 days of average volume to cover
- 3. Breakout on heavy volume: fail. No close above the A$18.22 pivot on 1.5x volume in the last 5 sessions; close is -11.7% from the pivot
- 4. Market direction: fail. XJO in a downtrend: below its 200-day average
- 5. Liquid enough to trade: pass. A$41.8m average daily turnover over 20 sessions
- 6. Relative strength: pass. Beat the S&P/ASX 200 by 5.9 points over 3 months
Quality compounders
WatchScore 46rank 6 of 1171
- 1. High return on equity: unknown. Return on equity cannot be measured: it needs net profit, equity at both ends of the year and, outside banks, insurers and other financials, equity of at least 10% of total assets
- 2. Healthy profit margin: pass. Net margin 40.9% (FY ending 2024-06-30)
- 3. Profit that turns into cash: unknown. Free cash flow or net profit is missing for the period
- 4. Little debt: unknown. Net debt cannot be measured: no aligned balance sheet with debt and cash
- 5. Liquid enough to trade: pass. A$41.8m average daily turnover over 20 sessions
- 6. Long-term uptrend: pass. Close A$16.09 vs 200-day average A$13.56 (+18.6%)
- 7. Revenue not shrinking: pass. Revenue +2.6% YoY (FY ending 2025-06-30)